---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000125"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T13:51:03.921962+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q2 product revenue $553.7M (+82% YoY); BRUKINSA sales $308M; settles BMS arbitration

## Summary
- Settled BMS-Celgene dispute: BMS transfers 23.3M BeiGene shares to BeiGene, no cash payment; arbitration dismissed.
- BRUKINSA global sales $308M (+139% YoY); U.S. sales $223.5M (+153% YoY); tislelizumab China sales $149.5M (+42.5% YoY).
- Net loss improved to $381.1M from $565.7M YoY; operating leverage driven by 82% revenue growth vs 15% expense growth.
- Regained full global rights to TIGIT inhibitor ociperlimab from Novartis; partnered with DualityBio for preclinical ADC.
- Cash, equivalents and short-term investments $3.5B at June 30, down from $4.5B at year-end 2022.

## SEC filing metadata
- accession: 0001651308-23-000125
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/0001651308-23-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/bgne-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000125
- JSON: https://secwatch.observer/filing/0001651308-23-000125.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000125.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported the three months ended June 30, 2023 results: revenue $553.7 million, net income $381.1 million, EPS $0.28 per share.
  - Period: the three months ended June 30, 2023
  - Revenue: $553.7 million
  - Net income: $381.1 million
  - EPS: $0.28 per share
  - Result: reported results
  source text: Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results • Recorded total product revenue of $554 million in the quarter, an increase of 82% from the prior-year period, driven by increased sales of BRUKINSA® worldwide • Global sales of BRUKINSA totaled $308 million in the quarter, a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/0001651308-23-000125-index.htm
- Material Agreements
  BeOne Medicines Ltd. entered into Settlement and Termination Agreement with Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, Celgene Logistics Sàrl (effective 2023-08-01).
  - Action: entry
  - Agreement: settlement
  - Counterparty: Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, Celgene Logistics Sàrl
  - Effective: 2023-08-01
  source text: On August 1, 2023, BeiGene, Ltd. ( "BeiGene") and its wholly-owned indirect subsidiary, BeiGene Switzerland GmbH, signed a Settlement and Termination Agreement (the “Agreement”) with Bristol-Myers Squibb Company (“BMS”), Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, and Celgene Logistics Sàrl (collectively with BMS, “BMS-Celgene”), relating to the termination of the parties’ ongoing contractual relationships
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000125/0001651308-23-000125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.